Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Currently, targeting therapy makes great advances for the treatment of TNBC, whereas more effective therapeutic targets are urgently needed. Cyclin B2 (CCNB2), which belongs to B-type cyclins, is known as a cell cycle regulator. CCNB2 is synthesized at G1 phase in cancer cells and downregulated at anaphase. The defects of CCNB2 led to the abnormal cell cycle and tumorigenesis. Though there are wide effects of CCNB2 on multiple types of tumors, the potential role of CCNB2 in TNBC progression is still unclear. Herein, we found that CCNB2 was highly expressed in human TNBC tissues and correlated with the prognosis and clinical pathological features including tumor size () and pTNM stage () of patients with TNBC. CCNB2 could promote the proliferation of TNBC cells in vitro and in mice. Our findings therefore confirmed the involvement of CCNB2 in TNBC progression and provided the evidence that CCNB2 could serve as a promising molecular target of TNBC.

中文翻译：

---

细胞周期蛋白 B2 (CCNB2) 在体外和体内刺激三阴性乳腺癌 (TNBC) 细胞的增殖

三阴性乳腺癌 (TNBC) 是最具侵袭性的乳腺癌类型。目前，靶向治疗在TNBC的治疗方面取得了很大进展，但迫切需要更有效的治疗靶点。细胞周期蛋白 B2 (CCNB2) 属于 B 型细胞周期蛋白，被称为细胞周期调节剂。CCNB2 在癌细胞的 G1 期合成并在后期下调。CCNB2的缺陷导致细胞周期异常和肿瘤发生。尽管 CCNB2 对多种类型的肿瘤有广泛的影响，但 CCNB2 在 TNBC 进展中的潜在作用仍不清楚。在此，我们发现 CCNB2 在人 TNBC 组织中高表达，并且与预后和包括肿瘤大小在内的临床病理特征相关。)和 pTNM 阶段 () TNBC 患者。CCNB2可以促进TNBC细胞在体外和小鼠体内的增殖。因此，我们的研究结果证实了 CCNB2 参与了 TNBC 的进展，并提供了 CCNB2 可以作为 TNBC 有希望的分子靶点的证据。